MDL-1620-RWS E.D. Mo. (Jan. 17, 2006). AstraZeneca accused our client KV Pharmaceutical Company of infringing two patents by filing an ANDA seeking approval to market a generic version of the blockbuster drug Toprol-XL (metoprolol succinate extended-release tablets), which in 2005 had U.S. sales of almost $1.3 billion. The district court ruled on summary judgment that both AstraZeneca patents were invalid for non-statutory (obviousness-type) double patenting, the one of the patents was further invalid as anticipated, and that both patents were unenforceable for inequitable conduct committed by AstraZeneca in failing to disclose to the P.T.O. an inventorship dispute in which, among other things, AstraZeneca told the Swedish Patent Office that metoprolol succinate had been invented by someone other than the named inventors.